Suzuken Co., Ltd.
Financial Summary for the Third Quarter of Fiscal Year Ending March 2026 [Japanese GAAP] (Consolidated)
For the third quarter of the fiscal year ending March 2026, consolidated net sales were 1,885.603 billion yen (2.6% increase YoY), operating income was 27.230 billion yen (8.6% decrease YoY), and net income attributable to owners of parent for the quarter was 31.014 billion yen (1.1% increase YoY).
Key Figures
- Net Sales: 1,885.603 billion yen (2.6% increase YoY)
- Operating Income: 27.230 billion yen (8.6% decrease YoY)
- Net Income Attributable to Owners of Parent for the Quarter: 31.014 billion yen (1.1% increase YoY)
AI要約
Overview of Performance
In the cumulative consolidated period of the third quarter of the fiscal year ending March 2026, net sales amounted to 1,885.603 billion yen (2.6% increase YoY). This growth was driven by the expansion of the prescription pharmaceutical market and contributions from new specialty pharmaceuticals, although sales of COVID-19 related products declined. Operating income was 27.230 billion yen (8.6% decrease YoY) due to cost increases from rising pharmaceutical procurement prices and higher outsourcing expenses amid inflationary trends. Ordinary income also decreased to 29.315 billion yen (5.2% decrease YoY). On the other hand, net income attributable to owners of parent for the quarter increased to 31.014 billion yen (1.1% increase YoY) due to recorded gains on sales of investment securities.
Segment Performance
The pharmaceutical wholesaling segment recorded net sales of 1,822.29 billion yen (2.7% increase YoY) and operating income of 22.792 billion yen (9.5% decrease YoY). The healthcare product development segment had net sales of 39.335 billion yen (3.2% decrease YoY) and operating income of 1.776 billion yen (28.0% decrease YoY). The regional medical and nursing care support segment posted net sales of 70.418 billion yen (0.8% decrease YoY) and operating income of 0.792 billion yen (25.6% increase YoY). The specialty pharmaceutical distribution consignment segment reported net sales of 326.186 billion yen (44.8% increase YoY) and operating income of 0.871 billion yen (36.3% increase YoY). The medical-related services segment recorded net sales of 32.036 billion yen (0.3% increase YoY) and operating income of 0.929 billion yen (11.7% increase YoY).
Overview of Financial Position
Total assets increased by 193.632 billion yen from the previous consolidated fiscal year-end to 1,307.463 billion yen, mainly due to increases in cash and deposits, notes and accounts receivable. Total liabilities rose by 195.843 billion yen to 902.254 billion yen. Net assets decreased by 2.211 billion yen to 405.209 billion yen, reflecting reductions from dividend payments and share buybacks, partially offset by the recognition of quarterly net income.
Shareholder Returns and Share Buyback
The shareholder return policy is based on stable dividend continuation, aiming for a total return ratio of over 100% on average over three years through the fiscal year ending March 2026. On May 13, 2025, a resolution was made to acquire treasury stock, and by the end of December 2025, approximately 3.57 million shares (purchase price of 20.385 billion yen) had been acquired. The acquisition limit is 5,200,000 shares, up to 26 billion yen, and the acquisition period is from May 15, 2025, to March 19, 2026.
Outlook
There is no revision to the consolidated earnings forecast for the fiscal year ending March 2026. Net sales are projected at 2,468.0 billion yen (2.8% increase YoY), operating income at 33.6 billion yen (9.5% decrease YoY), ordinary income at 35.1 billion yen (9.6% decrease YoY), and net income attributable to owners of parent at 32.8 billion yen (4.9% decrease YoY).
